A Phase III Randomized, Double-Blind Trial of Chemoembolization With or Without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients With and Without Vascular Invasion.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 11 Mar 2018
At a glance
- Drugs Sorafenib (Primary) ; Cisplatin; Doxorubicin; Mitomycin
- Indications Liver cancer
- Focus Therapeutic Use
- 02 Feb 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Jul 2018.
- 07 Feb 2013 New source identified and integrated (Mayo Clinic record: 10-004516).
- 11 Jul 2012 Planned end date changed from 1 Sep 2012 to 1 Feb 2018 as reported by ClinicalTrials.gov.